Acura Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Acura Pharmaceuticals generated cash of $0, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year.
Cash Flow
| 2013 | -13.67M | 6.25M | 12.28M |
|---|---|---|---|
| 2014 | -11.04M | -2K | -520K |
| 2015 | -3.68M | 108K | 5.29M |
| 2016 | -5.56M | 10.79M | -2.53M |
| 2017 | -4.51M | 309K | 1.24M |
| 2018 | -3.90M | 0 | 1.77M |
| 2019 | -618K | 0 | 1.38M |
| 2020 | -719K | 0 | 270K |
| 2021 | -742K | 0 | 394K |
| 2022 | 0 | 0 | 0 |
ACUR Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 65K | 413K | 862K | 91K | 2.22M | 5.18M | 2.48M | 774K | 12.34M | 7.47M |
Operating activities | ||||||||||
Net income | 0 | -879K | -1.20M | -3.77M | -3.84M | -5.68M | -7.38M | -4.98M | -13.20M | -13.90M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 90K | 125K | 273K | 280K | 294K | 345K | 332K | 274K | 134K |
Stock-based compensation expense | 0 | 58K | 36K | 108K | 0 | 464K | 588K | 606K | 890K | 1.21M |
| Deferred income tax benefit | 0 | 58K | 36K | 108K | 0 | 464K | 588K | 606K | 890K | 1.21M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 469K | -399K | 44K | -66K | 23K | 19K | -69K | 118K | -194K |
Inventories | 0 | -469K | 399K | -44K | 0 | 103K | -59K | -302K | -254K | -282K |
Accounts payable | 0 | 161K | -206K | -368K | 602K | -74K | -33K | -107K | -57K | -720K |
Cash generated by operating activities | 0 | -742K | -719K | -618K | -3.90M | -4.51M | -5.56M | -3.68M | -11.04M | -13.67M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.52M | -2.20M | -7.61M |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | -75K | -214K | -2.13M | -23K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 103K | 0 | 14K | 2M | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 309K | 10.79M | 108K | -2K | 6.25M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 3K | 3K | 14K | 2K | 4M | 1K | 7.86M | 1K | 1K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -8 | -2 | 0 | 0 | 0 | 0 | 0 | -529 | 0 |
Repayments of term debt | 0 | -17K | -269K | 1.37M | -2.57M | -2.76M | -2.54M | -1.96M | 0 | 0 |
Cash used in financing activities | 0 | 394K | 270K | 1.38M | 1.77M | 1.24M | -2.53M | 5.29M | -520K | 12.28M |
Net Change In Cash | 0 | -348K | -449K | 771K | -2.12M | -2.96M | 2.69M | 1.71M | -11.56M | 4.86M |
Cash at end of period | 65K | 65K | 413K | 862K | 91K | 2.22M | 5.18M | 2.48M | 774K | 12.34M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |